Concord Biotech Ltd (CONCORDBIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10038977,
    "name": "Concord Biotech",
    "stock_name": "Concord Biotech",
    "full_name": "Concord Biotech Ltd",
    "name_url": "stocks-analysis/concord-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,417.75",
    "chg": 14.7,
    "chgp": "1.05%",
    "dir": 1,
    "prev_price": "1,403.05",
    "mcapval": "14,831.96 Cr",
    "mcap": "Small Cap",
    "scripcode": 543960,
    "symbol": "CONCORDBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE338H01029",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "31.9 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/concord-biotech-10038977-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Biotech’s Evaluation Revised Amidst Challenging Financial and Market Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-downgraded-to-strong-sell-amid-weak-financial-and-technical-indicators-3733005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordBiotech_mojoScore_3733005.png",
        "date": "2025-11-27 10:06:45",
        "description": "Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial results and market performance. The company’s assessment metrics have shifted downward, influenced by a combination of valuation concerns, financial trends, and technical indicators."
      },
      {
        "title": "Concord Biotech Q2 FY26: Sharp Profit Decline Amid Revenue Volatility Raises Red Flags",
        "link": "https://www.marketsmojo.com/news/result-analysis/concord-biotech-q2-fy26-sharp-profit-decline-amid-revenue-volatility-raises-red-flags-3718506",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ConcordBiotech_quaterlyResult_3718506.png",
        "date": "2025-11-15 11:01:09",
        "description": "Concord Biotech Limited, the Ahmedabad-based pharmaceutical and biotechnology company with a market capitalisation of ₹15,244 crores, reported a consolidated net profit of ₹63.58 crores for Q2 FY26, representing a sharp decline of 33.59% year-on-year from ₹95.74 crores in Q2 FY25. The quarter-on-quarter performance showed a recovery of 44.30% from Q1 FY26's ₹44.06 crores, though this improvement fails to mask deeper concerns about the company's earnings trajectory. The stock has responded negatively to the company's recent performance, declining 20.80% over the past year and underperforming the broader pharmaceuticals sector by 24.56 percentage points."
      },
      {
        "title": "How has been the historical performance of Concord Biotech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-biotech-3699794",
        "imagepath": "",
        "date": "2025-11-13 23:50:41",
        "description": "Answer:\nThe historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.\n\nBreakdown:\nConcord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 t..."
      },
      {
        "title": "Why is Concord Biotech falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-concord-biotech-fallingrising-3654007",
        "imagepath": "",
        "date": "2025-10-29 02:04:39",
        "description": "As of 28-Oct, Concord Biotech Ltd's stock price is currently at 1,432.20, reflecting a decrease of 26.2 points or 1.8%. The stock has been underperforming significantly, with a consecutive decline over the last four days, resulting in a 5.9% drop in the past week. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock is close to its 52-week low, being only 4.34% away from that point. The company's recent financial performance has raised concerns, as its PAT for the quarter has fallen by 52.6% compared to the previous four-quarter average, and net sales have reached their lowest at Rs 203.99 crore. Despite having a high return on equity (ROE) of 19.76% and a low debt-to-equity ratio, the stock's valuation appears expensive with a price-to-book value of 8.3, contributing to its negative sentiment among investors.\n\nIn the broader market context, ..."
      },
      {
        "title": "Concord Biotech Faces Technical Shift Amid Declining Sales and Profitability Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-stock-downgraded-to-strong-sell-amid-bearish-trends-3643164",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ConcordBiotech_mojoScore_3643164.png",
        "date": "2025-10-24 08:44:44",
        "description": "Concord Biotech has recently experienced a change in evaluation, reflecting a shift in its technical outlook. The company reported a significant decline in net sales and profit after tax for the latest quarter, alongside a high price-to-book ratio, indicating challenges in maintaining competitive growth."
      },
      {
        "title": "How has been the historical performance of Concord Biotech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-biotech-3641961",
        "imagepath": "",
        "date": "2025-10-23 22:46:48",
        "description": "Answer:\nThe historical performance of Concord Biotech shows a consistent growth trend in net sales and profitability over the past four years.\n\nBreakdown:\nConcord Biotech's net sales increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trajectory. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew, from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25. Operating profit (PBDIT) saw significant growth, climbing from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, while profit before tax increased from 241.16 Cr to 495.87 Cr. The profit after tax also rose from 178.57 Cr in Mar'22 to 372.96 Cr in Mar'25, indicating improved profitability margins, with the PAT margin reaching 30.97% in Mar'25. On the balance sheet, total assets grew from 1,312.79 Cr in Mar'22 t..."
      },
      {
        "title": "Why is Concord Biotech falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-concord-biotech-fallingrising-3624433",
        "imagepath": "",
        "date": "2025-10-16 00:02:56",
        "description": "As of 15-Oct, Concord Biotech Ltd's stock price is currently at 1,509.70, reflecting a decrease of 6.05 points or 0.4%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 5.67% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The delivery volume has also significantly decreased by 51.26% compared to the 5-day average, suggesting a lack of investor interest. Financially, the company has reported poor quarterly performance, with a substantial drop in profit before tax and net sales, contributing to a negative sentiment around the stock. Despite having a high return on equity and low debt-to-equity ratio, the overall outlook remains bleak due to its poor long-term growth prospects and high valuation metrics.\n\nIn the broader market context..."
      },
      {
        "title": "How has been the historical performance of Concord Biotech?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-concord-biotech-3616279",
        "imagepath": "",
        "date": "2025-10-13 22:49:05",
        "description": "Answer:\nThe historical performance of Concord Biotech shows a consistent growth trend across various financial metrics from March 2022 to March 2025.\n\nBreakdown:\nConcord Biotech's net sales have increased significantly from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025. The total operating income followed a similar upward trajectory, reaching INR 1,200.09 crore in March 2025, up from INR 712.93 crore in March 2022. Total expenditure, excluding depreciation, also rose from INR 439.66 crore in March 2022 to INR 693.76 crore in March 2025. Operating profit (PBDIT) has shown a robust increase, climbing from INR 296.69 crore in March 2022 to INR 550.78 crore in March 2025, while profit before tax rose from INR 241.16 crore to INR 495.87 crore in the same period. The profit after tax saw a substantial increase from INR 178.57 crore in March 2022 to INR 372.96 crore in March 2025. The earnings..."
      },
      {
        "title": "Is Concord Biotech technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-concord-biotech-technically-bullish-or-bearish-3602388",
        "imagepath": "",
        "date": "2025-10-08 08:11:25",
        "description": "As of 7 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish signals. The daily moving averages also reflect a bearish outlook. However, the On-Balance Volume (OBV) shows bullish strength on both weekly and monthly time frames, suggesting some underlying buying pressure. Overall, the lack of strong bullish indicators and the presence of bearish signals in multiple areas indicate a cautious stance on Concord Biotech...."
      }
    ],
    "total": 329,
    "sid": "10038977",
    "stock_news_url": "https://www.marketsmojo.com/news/concord-biotech-10038977"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "19-Nov-2025",
      "details": "Transcript of Q2FY26 earning call held on November 14 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "15-Nov-2025",
      "details": "Q2FY26 Earnings Call Audio",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-Nov-2025",
      "details": "Newspaper clippings of Q2 FY25-26",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Concord Biotech Ltd has declared <strong>1070%</strong> dividend, ex-date: 03 Sep 25",
          "dt": "2025-09-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Biotech’s Evaluation Revised Amidst Challenging Financial and Market Trends

2025-11-27 10:06:45

Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent financial results and market performance. The company’s assessment metrics have shifted downward, influenced by a combination of valuation concerns, financial trends, and technical indicators.

Concord Biotech Q2 FY26: Sharp Profit Decline Amid Revenue Volatility Raises Red Flags

2025-11-15 11:01:09

Concord Biotech Limited, the Ahmedabad-based pharmaceutical and biotechnology company with a market capitalisation of ₹15,244 crores, reported a consolidated net profit of ₹63.58 crores for Q2 FY26, representing a sharp decline of 33.59% year-on-year from ₹95.74 crores in Q2 FY25. The quarter-on-quarter performance showed a recovery of 44.30% from Q1 FY26's ₹44.06 crores, though this improvement fails to mask deeper concerns about the company's earnings trajectory. The stock has responded negatively to the company's recent performance, declining 20.80% over the past year and underperforming the broader pharmaceuticals sector by 24.56 percentage points.

How has been the historical performance of Concord Biotech?

2025-11-13 23:50:41

Answer: The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years. Breakdown: Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 t...

Why is Concord Biotech falling/rising?

2025-10-29 02:04:39

As of 28-Oct, Concord Biotech Ltd's stock price is currently at 1,432.20, reflecting a decrease of 26.2 points or 1.8%. The stock has been underperforming significantly, with a consecutive decline over the last four days, resulting in a 5.9% drop in the past week. It is also trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock is close to its 52-week low, being only 4.34% away from that point. The company's recent financial performance has raised concerns, as its PAT for the quarter has fallen by 52.6% compared to the previous four-quarter average, and net sales have reached their lowest at Rs 203.99 crore. Despite having a high return on equity (ROE) of 19.76% and a low debt-to-equity ratio, the stock's valuation appears expensive with a price-to-book value of 8.3, contributing to its negative sentiment among investors. In the broader market context, ...

Concord Biotech Faces Technical Shift Amid Declining Sales and Profitability Challenges

2025-10-24 08:44:44

Concord Biotech has recently experienced a change in evaluation, reflecting a shift in its technical outlook. The company reported a significant decline in net sales and profit after tax for the latest quarter, alongside a high price-to-book ratio, indicating challenges in maintaining competitive growth.

How has been the historical performance of Concord Biotech?

2025-10-23 22:46:48

Answer: The historical performance of Concord Biotech shows a consistent growth trend in net sales and profitability over the past four years. Breakdown: Concord Biotech's net sales increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trajectory. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew, from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25. Operating profit (PBDIT) saw significant growth, climbing from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, while profit before tax increased from 241.16 Cr to 495.87 Cr. The profit after tax also rose from 178.57 Cr in Mar'22 to 372.96 Cr in Mar'25, indicating improved profitability margins, with the PAT margin reaching 30.97% in Mar'25. On the balance sheet, total assets grew from 1,312.79 Cr in Mar'22 t...

Why is Concord Biotech falling/rising?

2025-10-16 00:02:56

As of 15-Oct, Concord Biotech Ltd's stock price is currently at 1,509.70, reflecting a decrease of 6.05 points or 0.4%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total decline of 5.67% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The delivery volume has also significantly decreased by 51.26% compared to the 5-day average, suggesting a lack of investor interest. Financially, the company has reported poor quarterly performance, with a substantial drop in profit before tax and net sales, contributing to a negative sentiment around the stock. Despite having a high return on equity and low debt-to-equity ratio, the overall outlook remains bleak due to its poor long-term growth prospects and high valuation metrics. In the broader market context...

How has been the historical performance of Concord Biotech?

2025-10-13 22:49:05

Answer: The historical performance of Concord Biotech shows a consistent growth trend across various financial metrics from March 2022 to March 2025. Breakdown: Concord Biotech's net sales have increased significantly from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025. The total operating income followed a similar upward trajectory, reaching INR 1,200.09 crore in March 2025, up from INR 712.93 crore in March 2022. Total expenditure, excluding depreciation, also rose from INR 439.66 crore in March 2022 to INR 693.76 crore in March 2025. Operating profit (PBDIT) has shown a robust increase, climbing from INR 296.69 crore in March 2022 to INR 550.78 crore in March 2025, while profit before tax rose from INR 241.16 crore to INR 495.87 crore in the same period. The profit after tax saw a substantial increase from INR 178.57 crore in March 2022 to INR 372.96 crore in March 2025. The earnings...

Is Concord Biotech technically bullish or bearish?

2025-10-08 08:11:25

As of 7 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish signals. The daily moving averages also reflect a bearish outlook. However, the On-Balance Volume (OBV) shows bullish strength on both weekly and monthly time frames, suggesting some underlying buying pressure. Overall, the lack of strong bullish indicators and the presence of bearish signals in multiple areas indicate a cautious stance on Concord Biotech....

View All News